In EDS ansehen

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B

Gespeichert in:
Bibliographische Detailangaben
Titel: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Autoren: Dent, J, Tai, DI, Liaw, YF, Leung, NWY, Chang, TT, Guan, R, Lai, CL, Chien, RN, Ng, KY, Roman, L, Edmundson, S
Quelle: Gastroenterology. 119:172-180
Verlagsinformationen: Elsevier BV, 2000.
Publikationsjahr: 2000
Schlagwörter: Adult, Asian Continental Ancestry Group, Male, 0301 basic medicine, Hepatitis C, Chronic - Blood - Drug Therapy - Virology, Ethnic Groups, Drug Administration Schedule, 12. Responsible consumption, 03 medical and health sciences, Lamivudine - Administration & Dosage - Adverse Effects - Therapeutic Use, Reference Values, Viral - Antagonists & Inhibitors - Blood, Humans, Serologic Tests, 0303 health sciences, Dna, Chronic - Blood - Drug Therapy - Virology, Hepatitis C, Hepatitis B Virus - Genetics, Hepatitis B E Antigens - Analysis - Genetics, Reverse Transcriptase Inhibitors - Administration & Dosage - Adverse Effects - Therapeutic Use, 3. Good health, Mutation, Female, Dna, Viral - Antagonists & Inhibitors - Blood, Alanine Transaminase - Blood
Beschreibung: Background & Aims: One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. However, the effects of prolonged therapy are unknown. Methods: A total of 334 Asian patients with chronic hepatitis B from a previously reported 1-year study were randomized to receive either lamivudine (100 or 25 mg) or placebo for another year. The effects of treatment on serum HBV-DNA suppression, alanine transaminase (ALT) normalization, and hepatitis B e antigen (HBeAg) seroconversion were measured. The presence of YMDD variant HBV and its effect were also determined. Results: A significantly greater proportion of patients achieved sustained HBV-DNA suppression and ALT normalization with 100 mg lamivudine daily for 2 years compared with lamivudine for 1 year followed by placebo for the second year ( P P Conclusions: Treatment with lamivudine for 2 years is both well tolerated and efficacious in patients with chronic hepatitis B. GASTROENTEROLOGY 2000;119:172-180
Publikationsart: Article
Sprache: English
ISSN: 0016-5085
DOI: 10.1053/gast.2000.8559
Zugangs-URL: https://www.gastrojournal.org/article/S0016-5085(00)97619-4/pdf
https://core.ac.uk/display/37982747
https://www.sciencedirect.com/science/article/pii/S0016508500976194
https://www.ncbi.nlm.nih.gov/pubmed/10889166
https://www.gastrojournal.org/article/S0016-5085(00)97619-4/abstract
https://www.cabdirect.org/cabdirect/abstract/20002016925
http://hdl.handle.net/10722/162436
Rights: Elsevier TDM
Dokumentencode: edsair.doi.dedup.....ab91ad5ac1fcb0b24d0ea83d8f35c2a6
Datenbank: OpenAIRE
Beschreibung
Abstract:Background & Aims: One-year lamivudine therapy significantly suppressed hepatitis B virus (HBV) replication, improved hepatic necroinflammatory activity, and prevented progression of fibrosis. However, the effects of prolonged therapy are unknown. Methods: A total of 334 Asian patients with chronic hepatitis B from a previously reported 1-year study were randomized to receive either lamivudine (100 or 25 mg) or placebo for another year. The effects of treatment on serum HBV-DNA suppression, alanine transaminase (ALT) normalization, and hepatitis B e antigen (HBeAg) seroconversion were measured. The presence of YMDD variant HBV and its effect were also determined. Results: A significantly greater proportion of patients achieved sustained HBV-DNA suppression and ALT normalization with 100 mg lamivudine daily for 2 years compared with lamivudine for 1 year followed by placebo for the second year ( P P Conclusions: Treatment with lamivudine for 2 years is both well tolerated and efficacious in patients with chronic hepatitis B. GASTROENTEROLOGY 2000;119:172-180
ISSN:00165085
DOI:10.1053/gast.2000.8559